Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542905 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL3718198 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL30020222 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL12040028 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL13330619 | 0.80 | CHRM2 (0.49) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL29080 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL31645911 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL28883610 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL29349628 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM | |
| SCHEMBL10356935 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CHRM2KDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | SMN1; SMN2 1758/4885L3MBTL1 3238/4885CHRM2 930/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SMN1; SMN2 4412/4885L3MBTL1 3576/4885CHRM2 4799/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SMN1; SMN2 4412/4885L3MBTL1 3576/4885CHRM2 4799/4885 |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | SMN1; SMN2 3749/4885L3MBTL1 2335/4885CHRM2 226/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SMN1; SMN2 4412/4885L3MBTL1 3576/4885CHRM2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.